Population health management and precision medicine are more alike than different, and closer collaboration could produce impactful results. According to Jonathan Sheldon, Global VP of Healthcare at Oracle Health Sciences, “Precision medicine gives us the molecular tools to phenotype diseases, which you can then predict and manage at the population level. Genomics gives you that level of precision that is often lacking in risk stratification algorithms. They really enhance one another.”
A suite of introductory resources has been produced by the Genomics in Mainstream Medicine Working Group of the UK-based PHG Foundation. Each ‘factsheet’ is tailored to a specific medical specialty and seeks to raise awareness of genomic medicine and its impact on clinical care.
A bill that protects Canadians from discrimination based on genetic information was passed in parliament yesterday by a vote of 222-60. Bill S-201, which was already passed in the Senate, bars health and life insurance companies from requiring a person to undergo genetic testing or to disclose the results of previous tests. The legislation also prohibits anyone from sharing genetic testing results without written consent, with exceptions for physicians and researchers. Prior to Bill S-201, Canada was the only G7 country without specific protections against genetic discrimination.
CBC documentary series “The Nature of Things” featured an in-depth look at the BC Cancer Agency’s Personalized Onco-Genomics (POG) program in the documentary “Cracking Cancer.” With the aim of identifying and treating cancer-causing mutations specific to each patient, these cutting-edge clinical trials hold the promise of personalized cancer care.
In a report released by the U.S. National Academy of Sciences and National Academy of Medicine, an expert committee of scientists and bioethicists from 10 countries has laid out a set of principles to inform future manipulations of the human genome. Preaching caution, not prohibition, they recommend that regulators tightly control rather than entirely ban the option of making changes to human DNA to prevent genetic disease and disability.
A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes. This pivotal guideline will help establish standard molecular biomarker testing, guide targeted therapy decisions, and advance personalized care for patients with colorectal cancer.
CDN and AUS prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50% of patients within five years. The findings show that the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated cancers and resistant to therapy from the onset.
Dana-Farber scientists have released new research in which 56% of brain tumor samples from children had genetic abnormalities that could influence diagnosis and/or treatment. This suggests that more effective care could be identified by sequencing the genes of the tumors and selecting treatments that target each tumor’s specific genetic abnormalities.
Researchers and physicians from across the U.S. have formed a new consortium dubbed NSIGHT (Newborn Sequencing in Genomic Medicine and Public Health) to explore the implications, challenges, and opportunities associated with the possible use of genomic sequence information of newborns.
Genomics research holds the key to meeting many of the global healthcare challenges of the years ahead. The major trends outlined will shape the healthcare and life science markets in the field of genomics and foster advancements in personalized medicine.